FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214623532> ?p ?o ?g. }

• W3214623532 endingPage "1771" @default.
• W3214623532 startingPage "1771" @default.
• W3214623532 abstract "Abstract Introduction: Bendamustine is a hybrid alkylating agent with high efficacy in different haematological malignancies, especially for lymphomas. Data about the capacity of peripheral blood stem cell (PBSC) mobilization or a possible stem cell toxicity after the use of bendamustine are unclear, with sufficient number of PBSC after bendamustine- rituximab (B-R) combination used in first line but with scarce information in relapse, especially with the use of bendamustine immediately before mobilization. The aim of this study was to evaluate the influence on PBSC mobilization of bendamustine as the last previous regimen used before the collection of PBSC. Methods: This is a retrospective, multicentre study, which includes patients from 8 different GELTAMO centres in Spain. Forty-eight lymphoma patients who received bendamustine followed immediately by stem cell mobilization (SCM) were included. A single-centre control group of consecutive patients was included, matched by histology, age and number of previous lines; HIV+ patients were excluded. Results: We included 83 patients, 45 in the bendamustine group and 38 in the control group. Table 1 shows patient´s characteristics. Both groups are adequately balanced. No patients received previous lenalidomide, and none patient had previous transplant. In the bendamustine group, the median number of cycles administered was 4 (range 2-6). In 8 patients of the bendamustine group and 12 in the control group the mobilization was programmed after first-line treatment. In the remaining cases, mobilizations were performed after 1 st or 2 nd relapse treatment. In most of the patients, the mobilization regimen was performed only with G-CSF, although 7 patients in the control and 3 patients in bendamustine groups received alternative regimens such as ESHAP, DHAP or ICE. Ten patients in the bendamustine group received plerixafor as part of the 1 st attempt mobilization regimen. Median number of apheresis with the first attempt of mobilization was 1.5 in the bendamustine group vs 1.3 in the control group. In bendamustine group 8 patients didn't go to apheresis due to a low pre-mobilization CD34+ cell count in peripheral blood, compared with 2 patients in control group. Median pre-mobilization CD34+ cells and median number of mobilized CD34 cells obtained was significative lower with in bendamustine group (Table 1). Moreover, 10 patients in this group didn't mobilized with 1 st attempt (and in 4 of them and neither with the second mobilization attempt), compared with only 2 in the control group. Mobilization failure in the bendamustine group was more frequent in certain lymphoma subtypes (among the 10 failures, HL and FL were the most frequent, 40%, p=0.07, and 50%, p=0.051 respectively), and was also associated with number of previous lines of therapy (HR 4,1; p= 0.041), since 90% of the failures were patients mobilized at relapse, and only 1 as 1st line consolidation. No relationship was found between stage, doses, or number of cycles of bendamustine administered. Conclusion: Our results show that the collection of sufficient numbers of PBSC could be affected by the use of bendamustine immediately prior to mobilization, especially in more pre-treated patients. We continue working on expanding our series to confirm these results. Figure 1 Figure 1. Disclosures Bastos-Oreiro: Kite: Speakers Bureau; Gilead: Honoraria; BMS-Celgene: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; F. Hoffmann-La Roche: Honoraria, Research Funding, Speakers Bureau; Takeda: Speakers Bureau; Novartis: Honoraria, Speakers Bureau. Salar: Roche: Consultancy, Speakers Bureau; Gilead: Research Funding; Janssen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau. Sancho: Roche, Janssen, Celgene-BMS, Gilead, Novartis, Takeda: Honoraria, Speakers Bureau; Roche, Janssen, Celgene-BMS, Gilead, Novartis, Incyte, Beigene: Speakers Bureau." @default.
• W3214623532 created "2021-11-22" @default.
• W3214623532 creator A5009164884 @default.
• W3214623532 creator A5010206363 @default.
• W3214623532 creator A5023818951 @default.
• W3214623532 creator A5034861019 @default.
• W3214623532 creator A5043084173 @default.
• W3214623532 creator A5048137234 @default.
• W3214623532 creator A5054200855 @default.
• W3214623532 creator A5076514135 @default.
• W3214623532 creator A5077730260 @default.
• W3214623532 creator A5083191976 @default.
• W3214623532 creator A5083592777 @default.
• W3214623532 creator A5084784467 @default.
• W3214623532 date "2021-11-05" @default.
• W3214623532 modified "2023-10-12" @default.
• W3214623532 title "Impact of the Use of Bendamustine Immediately before the Collection of Hematopoietic Stem Cells in Lymphoma. a Study By the Geltamo Group" @default.
• W3214623532 doi "https://doi.org/10.1182/blood-2021-150769" @default.
• W3214623532 hasPublicationYear "2021" @default.
• W3214623532 type Work @default.
• W3214623532 sameAs 3214623532 @default.
• W3214623532 citedByCount "1" @default.
• W3214623532 countsByYear W32146235322022 @default.
• W3214623532 crossrefType "journal-article" @default.
• W3214623532 hasAuthorship W3214623532A5009164884 @default.
• W3214623532 hasAuthorship W3214623532A5010206363 @default.
• W3214623532 hasAuthorship W3214623532A5023818951 @default.
• W3214623532 hasAuthorship W3214623532A5034861019 @default.
• W3214623532 hasAuthorship W3214623532A5043084173 @default.
• W3214623532 hasAuthorship W3214623532A5048137234 @default.
• W3214623532 hasAuthorship W3214623532A5054200855 @default.
• W3214623532 hasAuthorship W3214623532A5076514135 @default.
• W3214623532 hasAuthorship W3214623532A5077730260 @default.
• W3214623532 hasAuthorship W3214623532A5083191976 @default.
• W3214623532 hasAuthorship W3214623532A5083592777 @default.
• W3214623532 hasAuthorship W3214623532A5084784467 @default.
• W3214623532 hasConcept C126322002 @default.
• W3214623532 hasConcept C129470790 @default.
• W3214623532 hasConcept C13373296 @default.
• W3214623532 hasConcept C141071460 @default.
• W3214623532 hasConcept C143998085 @default.
• W3214623532 hasConcept C170493617 @default.
• W3214623532 hasConcept C2776694085 @default.
• W3214623532 hasConcept C2778828106 @default.
• W3214623532 hasConcept C2779338263 @default.
• W3214623532 hasConcept C2780653079 @default.
• W3214623532 hasConcept C2780775027 @default.
• W3214623532 hasConcept C2781413609 @default.
• W3214623532 hasConcept C2781442060 @default.
• W3214623532 hasConcept C2911091166 @default.
• W3214623532 hasConcept C71924100 @default.
• W3214623532 hasConceptScore W3214623532C126322002 @default.
• W3214623532 hasConceptScore W3214623532C129470790 @default.
• W3214623532 hasConceptScore W3214623532C13373296 @default.
• W3214623532 hasConceptScore W3214623532C141071460 @default.
• W3214623532 hasConceptScore W3214623532C143998085 @default.
• W3214623532 hasConceptScore W3214623532C170493617 @default.
• W3214623532 hasConceptScore W3214623532C2776694085 @default.
• W3214623532 hasConceptScore W3214623532C2778828106 @default.
• W3214623532 hasConceptScore W3214623532C2779338263 @default.
• W3214623532 hasConceptScore W3214623532C2780653079 @default.
• W3214623532 hasConceptScore W3214623532C2780775027 @default.
• W3214623532 hasConceptScore W3214623532C2781413609 @default.
• W3214623532 hasConceptScore W3214623532C2781442060 @default.
• W3214623532 hasConceptScore W3214623532C2911091166 @default.
• W3214623532 hasConceptScore W3214623532C71924100 @default.
• W3214623532 hasIssue "Supplement 1" @default.
• W3214623532 hasLocation W32146235321 @default.
• W3214623532 hasOpenAccess W3214623532 @default.
• W3214623532 hasPrimaryLocation W32146235321 @default.
• W3214623532 hasRelatedWork W2013338985 @default.
• W3214623532 hasRelatedWork W2209934110 @default.
• W3214623532 hasRelatedWork W2286705501 @default.
• W3214623532 hasRelatedWork W2500228675 @default.
• W3214623532 hasRelatedWork W2803000479 @default.
• W3214623532 hasRelatedWork W2805808559 @default.
• W3214623532 hasRelatedWork W3032075616 @default.
• W3214623532 hasRelatedWork W3040634619 @default.
• W3214623532 hasRelatedWork W4253475188 @default.
• W3214623532 hasRelatedWork W4362658254 @default.
• W3214623532 hasVolume "138" @default.
• W3214623532 isParatext "false" @default.
• W3214623532 isRetracted "false" @default.
• W3214623532 magId "3214623532" @default.
• W3214623532 workType "article" @default.